New York, February 14, 2026, 14:27 EST — The market has closed.
- AbbVie ended Friday at $231.50, up 1.8%, notching its second straight session of gains.
- At the Piper Sandler immunology conference, executives pointed to a series of trial readouts slated for release later this year.
- Markets in the U.S. take a break Monday for Washington’s Birthday. Trading picks back up Tuesday.
AbbVie Inc. ended Friday with a 1.8% gain, finishing at $231.50. The stock, after reaching $234.69 during the session, wrapped up a two-day run near its highs. Volume totaled roughly 8.3 million shares.
AbbVie heads into a holiday-shortened U.S. trading week with its shares back over $230. The stock’s been volatile lately. Investors are zeroing in on upcoming clinical data—eager for any hints, whether they surface in conference Q&As or tucked inside formal filings.
This comes as large pharmaceutical companies are labeled both “defensive” and “data-driven”—a reputation that can unravel quickly if markets turn volatile. As for AbbVie, traders are likely to focus on its pipeline tempo once trading stirs again.
Friday saw AbbVie’s top immunology execs, Roopal Thakkar and Kori Wallace, fielding questions during Piper Sandler’s Virtual Novel Targets in Immunology Symposium. Piper Sandler’s David Amsellem steered the Q&A. He kicked things off with, “A good place to start… would be on data readouts as… the year progresses.” Seeking Alpha
AbbVie highlighted its Phase II trials in hidradenitis suppurativa (HS), a chronic inflammatory skin disorder, emphasizing these studies are key for evaluating efficacy and refining dosing. The company outlined a series of data releases slated for this year. Updates came as well on inflammatory bowel disease (IBD), along with details on its oral IL-23 inhibitor program—targeting a specific immune pathway—and its CAR-T cell initiatives. AbbVie also acknowledged the safety concerns tied to increased immune suppression as studies extend with longer follow-up periods.
AbbVie’s shares jumped nearly 3% Thursday, then tacked on an extra 1.8% Friday, a two-day rally that stood out during a volatile week for various sectors. Trading volume came in higher than usual, and the stock left most big pharma names behind in Friday’s session, MarketWatch data show.
But just because a conference puts a date on the calendar doesn’t mean the results will follow. A soft efficacy readout, any unexpected safety issue, or tepid demand in major new indications can knock a stock down in a hurry — particularly with investors treating big pharma as their supposed “steady” plays.
The week kicks off quietly, as the New York Stock Exchange shuts down Monday for Washington’s Birthday. With a shortened trading calendar, investors get less time to adjust ahead of the upcoming wave of healthcare news and fresh sector flows.
AbbVie faces an immediate hurdle—can ABBV stay above $230 when trading picks up on Tuesday, February 17? And after the conferences wind down, will buyers keep showing up, or does the market shift its focus to whatever catalyst comes next?
